The oncology diagnostic landscape is undergoing a radical transition from invasive tissue sampling to non-invasive molecular profiling. As we enter 2025, the Breast Cancer Liquid Biopsy Market has matured into a critical component of precision medicine, offering clinicians a "real-time" window into tumor evolution without the physical toll of traditional surgical biopsies. https://in.linkedin.com/company/data-bridge-market-research